LL-37 · Research brief

Choose LL-37 Vial Size — Dosing & Storage Guide

Real Peptides Research TeamEditorial

Updated July 9, 20268 min read

60 WORDS

Short answer

Key takeaways

LL-37 vial size should match your total peptide requirement plus 15–20% overhead for measurement loss and dead volume in syringes.
Reconstituted LL-37 remains stable for 28 days at 2–8°C when mixed with bacteriostatic water. Protocols longer than four weeks require mid-study reconstitution unless using large custom vials.
Target 2–2.5mg/mL working concentration to balance injection volume constraints with dosing precision using standard insulin syringes.
A 10mg vial reconstituted in 4mL bacteriostatic water yields 2.5mg/mL. Allowing 0.1mL draws for 250mcg doses with high precision.
Multi-week protocols exceeding one vial's 28-day window introduce batch-to-batch variance. Document reconstitution dates and bacteriostatic water lot numbers for reproducibility.
Calculate total peptide need before ordering: daily dose × study days × 1.2 overhead factor = minimum vial size required.

Here's something most peptide suppliers won't tell you upfront: the LL-37 vial size you choose determines whether your research protocol runs smoothly or becomes a daily exercise in reconstitution math and refrigerator Tetris. A 5mg vial might seem like the economical choice until you realize your 12-week study requires 84 individual doses and your reconstituted solution degrades after 14 days. The gap between selecting the right vial size and guessing comes down to three variables most researchers overlook entirely. Injection frequency, bacteriostatic water volume ratios, and the 28-day stability window for reconstituted peptides stored at 2–8°C.

We've worked with research teams ordering LL-37 for protocols ranging from single-dose pilot studies to multi-month longitudinal experiments. The vial size question comes up in every consultation, and the answer is never one-size-fits-all.

What vial size should I choose for LL-37 research peptides?

Choose LL-37 vial size based on your total peptide requirement across the study duration, factoring in the 28-day post-reconstitution stability window. For protocols requiring 2–5mg total peptide over four weeks, a 5mg vial provides adequate supply with minimal waste. Studies exceeding 5mg total or extending beyond four weeks should use 10mg vials to reduce reconstitution frequency and maintain dosing consistency. Lyophilized LL-37 remains stable at −20°C for 24–36 months; once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days.

Direct Answer: The Real Variables That Determine LL-37 Vial Size

The standard advice. "buy what fits your budget". Ignores the peptide stability reality. LL-37 (human cathelicidin antimicrobial peptide) is a 37-amino-acid chain that begins degrading the moment it contacts water, even with bacteriostatic preservatives. The 28-day post-reconstitution window isn't negotiable. It's the outer stability limit established through accelerated degradation testing at 2–8°C storage.

Most researchers underestimate their total peptide requirement. A protocol calling for 200mcg daily injections across 12 weeks requires 16.8mg of LL-37. Meaning a 5mg vial covers less than three weeks before you're reconstituting a second vial mid-study. Each new reconstitution introduces concentration variability, even when following identical mixing protocols.

This article covers the dosing math that determines vial size selection, the reconstitution volume ratios that affect injection precision, and the storage constraints that make or break protocol consistency across multi-week studies.

Calculate Your Total LL-37 Requirement Before Selecting Vial Size

Start with your per-dose requirement. Most LL-37 research protocols use 100–500mcg per administration. Multiply that by injection frequency (daily, every other day, twice weekly) and study duration in days. Add 15–20% overhead for measurement error, dead volume in syringes, and inevitable pipetting loss. That's your minimum peptide requirement.

For example: 250mcg daily for 8 weeks = 250mcg × 56 days = 14,000mcg = 14mg base requirement. Add 20% overhead = 16.8mg total. A single 10mg vial won't suffice. You need two 10mg vials or one custom-sized vial if your supplier offers precision sizing.

The 28-day reconstitution window creates a hard constraint. If your protocol spans longer than four weeks at a given vial, you're forced to reconstitute mid-study. This isn't catastrophic, but it introduces batch-to-batch concentration variance even when using identical bacteriostatic water volumes. Research teams aiming for maximum reproducibility should match vial size to study duration whenever possible. One vial, one reconstitution, consistent dosing from day 1 to endpoint.

Waste calculation matters more than most researchers assume. A 10mg vial reconstituted for a 6mg protocol leaves 4mg unused peptide that degrades past the 28-day mark. At current peptide pricing, that's $80–$120 of discarded compound per vial. Multiple small vials cost more per milligram but eliminate waste if your protocol allows phased reconstitution.

Reconstitution Volume and Concentration: Why Vial Size Affects Dosing Precision

Larger vials require proportionally more bacteriostatic water to achieve usable concentrations. And injection volume constraints mean you can't dilute indefinitely. Standard subcutaneous injection volumes range from 0.1mL to 0.5mL; anything above 0.5mL causes tissue discomfort and inconsistent absorption kinetics.

A 5mg vial reconstituted in 2mL bacteriostatic water yields 2.5mg/mL concentration. To administer 250mcg, you draw 0.1mL. The minimum measurable volume with standard insulin syringes. That's precise. A 10mg vial in 2mL yields 5mg/mL concentration; 250mcg now requires 0.05mL, which sits at the edge of measurement reliability for non-specialized syringes. You're forced to either use 4mL bacteriostatic water (dropping concentration to 2.5mg/mL) or accept reduced precision at low draw volumes.

Our team has found that 2–2.5mg/mL is the sweet spot for LL-37 research. Concentrated enough to minimize injection volume, dilute enough to allow precise draws with standard 0.3mL or 0.5mL insulin syringes marked in 0.01mL increments. Work backward from this target when choosing vial size. If your protocol requires 8mg total and you want 2mg/mL working concentration, you need 4mL reconstitution volume minimum. Which fits comfortably in a standard 10mL sterile vial but may require custom vial sizing for peptide suppliers who pre-fill specific volumes.

Bacteriostatic water itself has a shelf life. Typically 28 days post-opening when stored at room temperature, longer if refrigerated. Coordinating your peptide reconstitution schedule with bacteriostatic water expiration prevents the scenario where your peptide is stable but your diluent isn't.

LL-37 Vial Size: Research Protocol Comparison

Protocol Duration	Daily Dose	Total LL-37 Required	Recommended Vial Size	Reconstitution Schedule	Professional Assessment
2 weeks	200mcg	2.8mg + 20% overhead = 3.4mg	5mg vial	Single reconstitution, use within 14 days	Ideal for pilot studies. Minimal waste, single-batch consistency
4 weeks	250mcg	7mg + 20% overhead = 8.4mg	10mg vial	Single reconstitution, use across full 28-day window	Standard choice for most short-term protocols
8 weeks	300mcg	16.8mg + 20% overhead = 20.2mg	Two 10mg vials or one 25mg vial	Two reconstitutions at day 1 and day 29, or single large-volume reconstitution	Multi-vial approach reduces waste; single large vial maximizes consistency
12 weeks	500mcg	42mg + 20% overhead = 50.4mg	Five 10mg vials	Reconstitute one vial every 28 days	Long-duration studies require phased reconstitution. Document batch numbers for reproducibility
Single-dose pilot	1000mcg	1mg + minimal overhead	2mg vial (if available) or shared 5mg vial	Reconstitute only what's needed for immediate use	Smallest available size prevents waste; coordinate with other concurrent studies to share vials

What If: LL-37 Vial Sizing Scenarios

What If My Protocol Needs 6mg Total But Only 5mg and 10mg Vials Are Available?

Order the 10mg vial and reconstitute the full amount. The 4mg excess will degrade past day 28, but splitting your protocol across two vials (one 5mg reconstituted at study start, another mid-study) introduces greater concentration variance than accepting some waste. Consistent single-batch dosing outweighs the cost of unused peptide in most research contexts.

What If I'm Running Multiple Concurrent Studies With Different LL-37 Doses?

Reconstitute one large vial (10mg or 25mg) and aliquot into smaller sterile vials immediately after mixing. Label each aliquot with reconstitution date, concentration, and intended protocol. This reduces per-study waste while maintaining the single-reconstitution advantage. Aliquoted peptide follows the same 28-day stability window as the parent vial.

What If I Need to Pause My LL-37 Protocol Mid-Study?

Reconstituted LL-37 cannot be re-frozen. Peptide structure degrades irreversibly during freeze-thaw cycles. If you must pause for more than 28 days, discard the reconstituted solution and start fresh with a new vial when resuming. Lyophilized peptide in unopened vials remains stable at −20°C for 24+ months, so pausing doesn't affect your remaining supply.

The Blunt Truth About LL-37 Vial Size Selection

Here's the honest answer: most researchers choose vial size based on sticker price without calculating total protocol cost. And end up paying more. A 5mg vial that covers half your study and forces mid-protocol reordering costs more in shipping, handling time, and dosing inconsistency than buying the correctly sized vial upfront. The suppliers who push "budget-friendly" small vials without asking about your protocol duration aren't helping you. They're setting you up to reorder.

The 28-day post-reconstitution limit isn't a suggestion. We've seen research teams try to stretch reconstituted LL-37 to 35 or 40 days because "it still looks clear". Peptide degradation is invisible to the eye. Antimicrobial peptides lose functional activity through oxidation and aggregation long before visible precipitation occurs. If your data shows unexplained potency decline in the final week of a study, expired reconstituted peptide is the first variable to examine.

Buy what your protocol actually requires, reconstitute once if possible, and discard anything left past 28 days. Precision costs money. Imprecision costs credibility. For research-grade LL-37 and guidance on vial sizing for your specific protocol, explore our research peptide catalog and consult with our technical team before placing your first order.

The reality of peptide research is this: vial size is protocol design. Choose it last-minute and you compromise dosing consistency. Choose it deliberately and your study runs without reconstitution surprises, waste-related budget overruns, or mid-protocol concentration shifts. Most issues with LL-37 stability trace back to vial size mismatches, not peptide quality. If you're reconstituting more than once per 28-day period for a continuous protocol, your vial was undersized from the start.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Lyophilized LL-37 stored at −20°C in sealed vials remains stable for 24–36 months, depending on storage conditions and packaging integrity. Once the vial is opened or reconstituted with bacteriostatic water, the 28-day refrigerated stability window begins. Unopened lyophilized peptide does not require refrigeration during short-term transport (up to 72 hours at ambient temperature), but long-term storage should always be at −20°C or colder to prevent moisture absorption and oxidative degradation.

Sterile water lacks the benzyl alcohol preservative that inhibits bacterial growth in multi-dose vials, reducing the safe use window from 28 days to 24–48 hours after reconstitution. If your protocol involves single-dose immediate use, sterile water is acceptable. For any multi-day protocol, bacteriostatic water (0.9% benzyl alcohol) is required to maintain sterility and peptide stability across the full 28-day window. Never use tap or distilled water — both introduce contaminants and ions that accelerate peptide degradation.

Pricing varies by supplier, but 10mg vials typically cost 1.6–1.8× the price of 5mg vials — not double. Per-milligram cost decreases with vial size, meaning two 5mg vials cost 10–15% more than one 10mg vial for the same total peptide. When factoring in shipping, handling, and the consistency advantage of single-batch reconstitution, 10mg vials offer better value for protocols requiring more than 6mg total LL-37. Budget-conscious researchers should calculate cost per protocol, not cost per vial.

LL-37 is moderately photosensitive — prolonged exposure to direct light accelerates oxidative degradation of methionine and tryptophan residues in the peptide chain. Store reconstituted vials in a refrigerator away from interior lighting, or wrap the vial in aluminum foil if your refrigerator has continuous LED illumination. Lyophilized peptide in amber glass vials has built-in light protection; clear glass vials should be stored in their original packaging or a light-blocking container.

Yes, if both studies begin within the same 28-day window. Reconstitute the 10mg vial, calculate the volume needed for Study A, and transfer that volume to a separate sterile vial. The remaining solution stays in the original vial for Study B. Both aliquots follow the same 28-day stability timeline from the original reconstitution date. Label each vial with reconstitution date, concentration, and study identifier to prevent cross-contamination or dosing errors.

Freezing reconstituted peptide causes ice crystal formation that disrupts tertiary protein structure — the peptide may appear normal after thawing but has likely lost functional activity. Freeze-thaw cycles are irreversible; if reconstituted LL-37 has been frozen, discard it and prepare a fresh solution. This is why bacteriostatic water vials should never be stored in freezers despite their 28-day room-temperature limit — accidental freezing compromises future reconstitutions.

Visible signs include clouding, precipitation, or color change from clear to yellow-brown. Functional degradation occurs before visible changes — the peptide loses antimicrobial potency through oxidation and aggregation that HPLC can detect but visual inspection cannot. If you observe any cloudiness or particles, discard immediately. For critical studies, consider sending an aliquot for HPLC purity testing at day 14 and day 28 to establish degradation kinetics for your specific storage conditions.

Plan for 15–20% overhead above calculated need, but don’t over-purchase beyond one additional reconstitution cycle. A 12-week study requiring 18mg total should use two 10mg vials (20mg total), not three — the third vial would sit unused and the reconstituted solution from vial 2 would cover the overage. Excess lyophilized peptide has multi-year shelf life; excess reconstituted peptide expires in 28 days. Buy enough to cover your protocol plus one safety margin vial.

Some peptide suppliers offer custom synthesis at non-standard quantities (7mg, 15mg, 25mg) with minimum order quantities and lead times of 2–4 weeks. Custom sizing is cost-effective for large or recurring studies but impractical for one-off experiments. If your protocol requires an unusual total (e.g., 22mg), it’s typically faster and cheaper to order standard vials (two 10mg + one 5mg) and manage the slight excess than to wait for custom synthesis.

No — purity is determined during synthesis and verified by HPLC before lyophilization. A 5mg vial and a 25mg vial from the same synthesis batch have identical purity and amino acid sequence. Vial size affects only the amount of peptide per container, not its molecular integrity. What does affect quality is storage conditions post-manufacture: temperature excursions above −20°C during shipping or improper reconstitution technique introduce degradation regardless of vial size.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA